This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Hormone treatment to improve or maintain cognitive function in postmenopausal women has always been a contentious issue. In the late 1980s and 1990s, there was brief enthusiasm for hormones to be a potential prophylactic treatment for dementia, based on findings from cell culture, animal, small treatment, and observational studies.1
However, the tide turned when a large randomized placebo-controlled study (the Women's Health Initiative Memory Study or WHIMS) found an increased risk for dementia already after 1 year of combination hormone treatment in women over 65 years of age.1,2 This study also confirmed earlier reported increased risks with long-term hormone treatment for dangerous adverse events, such as cardiovascular disease, stroke, and breast cancer.2 The use of hormone treatment dropped by a third and NIH guidelines2 recommended that hormones, when indicated for severe perimenopausal symptoms, should be prescribed at the lowest dose for the shortest period possible to reduce these risks. So how long should surgically menopausal women, who often report severe menopausal symptoms, be treated?
In this issue of Neurology®, the Mayo Clinic team in Minnesota reports that surgical menopause overall increased the risk of dementia or cognitive impairment by 45% in a large observational follow-up study.3 When unilateral oophorectomy was performed before 41 years of age, there was an almost doubled risk and when it was done before 34 years of age, this risk was more than four times higher. For …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.